CompletedEUCTR 2008-001829-33
Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression
This historical record does not confirm current site availability.
Historical research recordFrance
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- France
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 300
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- France
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2008-001829-33
- Official title
Show the full official title
Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedFrance
Registry details
Historical country statuses
- France — Completed
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Intranasal Esketamine Added to Standard Care for Adults at Imminent Suicide Risk
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression